Oklahoma 2022 Regular Session

Oklahoma House Bill HB1005 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
3		-	HB1005 HFLR Page 1
4		-	BOLD FACE denotes Committee Amendments. 1
	3	+	Req. No. 5070 Page 1 1
5	4		2
6	5		3
7	6		4
8	7		5
9	8		6
10	9		7
11	10		8
12	11		9
13	12		10
14	13		11
15	14		12
16	15		13
17	16		14
18	17		15
19	18		16
20	19		17
21	20		18
22	21		19
23	22		20
24	23		21
25	24		22
26	25		23
27	26		24
28	27
29		-	HOUSE OF REPRESENTATIVES - FLOOR VERSION
30		-
31	28		STATE OF OKLAHOMA
32	29
33	30		1st Session of the 58th Legislature (2021)
34	31
35		-	HOUSE BILL 1005 By: Bush and Pae of the House
36		-
37		-	and
38		-
39		-	Montgomery of the Senate
	32	+	HOUSE BILL 1005 By: Bush
40	33
41	34
42	35
43	36
44	37
45	38		AS INTRODUCED
46	39
47	40		An Act relating to the Uniform Controlled Dangerous
48	41		Substances Act; amending 63 O.S. 2011, Section 2 -101,
49	42		as last amended by Section 1, Cha pter 101, O.S.L.
50	43		2020 (63 O.S. Supp. 2020, Section 2 -101), which
51	44		relates to definitions; defining term; modifying
52	45		definitions; amending 63 O.S. 2011, Section 2 -101.1,
53	46		which relates to drug paraphernalia; providing
54	47		exception; authorizing certain entities to engage in
55	48		harm-reduction services; requiring registration with
56	49		the State Department of Health; providing for certain
57	50		allowable activities for specified period of time ;
58	51		providing reporting requirements; directing
59	52		promulgation of rules; providing for codifi cation;
60	53		and declaring an emergency .
61	54
62	55
63	56
64	57
65	58
66	59
67	60		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
68	61		SECTION 1. AMENDATORY 63 O.S. 2011, Section 2 -101, as
69	62		last amended by Section 1, Chapter 101, O.S.L. 2020 (63 O.S. Supp.
70	63		2020, Section 2-101), is amended to read as follows:
	64	+	Section 2-101. As used in the Uniform Controlled Dangerous
	65	+	Substances Act:
	66	+	1. "Administer" means the direct application of a controlled
	67	+	dangerous substance, whether by injection, inhalation, ingestion or
71	68
72		-	HB1005 HFLR Page 2
73		-	BOLD FACE denotes Committee Amendments. 1
	69	+	Req. No. 5070 Page 2 1
74	70		2
75	71		3
76	72		4
77	73		5
78	74		6
79	75		7
80	76		8
81	77		9
82	78		10
83	79		11
84	80		12
85	81		13
86	82		14
87	83		15
88	84		16
89	85		17
90	86		18
91	87		19
92	88		20
93	89		21
94	90		22
95	91		23
96	92		24
97	93
98		-	Section 2-101. As used in the Uniform Controlled Dangerous
99		-	Substances Act:
100		-	1. "Administer" means the direct application of a controlled
101		-	dangerous substance, whether by injection, inhalation, ingestion or
102	94		any other means, to the body of a patient, animal or research
103	95		subject by:
104	96		a. a practitioner (or, in the presence of the
105	97		practitioner, by the authorized agent of the
106	98		practitioner), or
107	99		b. the patient or research subject at the direction and
108	100		in the presence of t he practitioner;
109	101		2. "Agent" means a peace officer appointed by and who acts on
110	102		behalf of the Director of the Oklahoma State Bureau of Narcotics and
111	103		Dangerous Drugs Control or an authorized person who acts on behalf
112	104		of or at the direction of a person who m anufactures, distributes,
113	105		dispenses, prescribes, administers or uses for scientific purposes
114	106		controlled dangerous substances but does not include a common or
115	107		contract carrier, public warehouser or employee thereof, or a person
116	108		required to register under th e Uniform Controlled Dangerous
117	109		Substances Act;
118	110		3. "Board" means the Advisory Board to the Director of the
119	111		Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
120	112		4. "Bureau" means the Oklahoma State Bureau of Narcotics and
121	113		Dangerous Drugs Control ;
	114	+	5. "Coca leaves" includes cocaine and any compound,
	115	+	manufacture, salt, derivative, mixture or preparation of coca
	116	+	leaves, except derivatives of coca leaves which do not contain
	117	+	cocaine or ecgonine;
122	118
123		-	HB1005 HFLR Page 3
124		-	BOLD FACE denotes Committee Amendments. 1
	119	+	Req. No. 5070 Page 3 1
125	120		2
126	121		3
127	122		4
128	123		5
129	124		6
130	125		7
131	126		8
132	127		9
133	128		10
134	129		11
135	130		12
136	131		13
137	132		14
138	133		15
139	134		16
140	135		17
141	136		18
142	137		19
143	138		20
144	139		21
145	140		22
146	141		23
147	142		24
148	143
149		-	5. "Coca leaves" includes cocaine and any compound,
150		-	manufacture, salt, derivative, mixture or preparation of coca
151		-	leaves, except derivatives of coca leav es which do not contain
152		-	cocaine or ecgonine;
153	144		6. "Commissioner" or "Director" means the Director of the
154	145		Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
155	146		7. "Control" means to add, remove or change the placement of a
156	147		drug, substance or immediate precursor under the Uniform Controlled
157	148		Dangerous Substances Act;
158	149		8. "Controlled dangerous subs tance" means a drug, substance or
159	150		immediate precursor in Schedules I through V of the Uniform
160	151		Controlled Dangerous Substances Act or any drug, substance or
161	152		immediate precursor listed either temporarily or permanently as a
162	153		federally controlled substance. A ny conflict between state and
163	154		federal law with regard to the particular schedule in which a
164	155		substance is listed shall be resolved in favor of state law;
165	156		9. "Counterfeit substance " means a controlled substance which,
166	157		or the container or labeling of which w ithout authorization, bears
167	158		the trademark, trade name or other identifying marks, imprint,
168	159		number or device or any likeness thereof of a manufacturer,
169	160		distributor or dispenser other than the person who in fact
170	161		manufactured, distributed or dispensed the sub stance;
171	162		10. "Deliver" or "delivery" means the actual, constructive or
172	163		attempted transfer from one person to another of a controlled
	164	+	dangerous substance or drug paraphernalia, whether or not there is
	165	+	an agency relationship;
	166	+	11. "Dispense" means to deliver a controlled dangerous
	167	+	substance to an ultimate user or human research subject by or
173	168
174		-	HB1005 HFLR Page 4
175		-	BOLD FACE denotes Committee Amendments. 1
	169	+	Req. No. 5070 Page 4 1
176	170		2
177	171		3
178	172		4
179	173		5
180	174		6
181	175		7
182	176		8
183	177		9
184	178		10
185	179		11
186	180		12
187	181		13
188	182		14
189	183		15
190	184		16
191	185		17
192	186		18
193	187		19
194	188		20
195	189		21
196	190		22
197	191		23
198	192		24
199	193
200		-	dangerous substance or drug paraphernalia, whether or not there is
201		-	an agency relationship;
202		-	11. "Dispense" means to deliver a controlled dangerous
203		-	substance to an ultimate user or human research subject by or
204	194		pursuant to the lawful order of a practitioner, including the
205	195		prescribing, administering, packaging, labeling or compounding
206	196		necessary to prepare the substance for such d istribution.
207	197		"Dispenser" is a practitioner who delivers a controlled dangerous
208	198		substance to an ultimate user or human research subject;
209	199		12. "Distribute" means to deliver other than by administering
210	200		or dispensing a controlled dangerous substance;
211	201		13. "Distributor" means a commercial entity engaged in the
212	202		distribution or reverse distribution of narcotics and dangerous
213	203		drugs and who complies with all regulations promulgated by the
214	204		federal Drug Enforcement Administration and the Oklahoma State
215	205		Bureau of Narcotics and Dangerous Drugs Control;
216	206		14. "Drug" means articles:
217	207		a. recognized in the official United States Pharmacopoeia
218	208		Pharmacopeia, official Homeopathic Pharmacopoeia of
219	209		the United States, or official National Formulary, or
220	210		any supplement to any of them ,
221	211		b. intended for use in the diagnosis, cure, mitigation,
222	212		treatment or prevention of disease in man or other
223	213		animals,
	214	+	c. other than food, intended to affect the structure or
	215	+	any function of the body of man or other animals, and
	216	+	d. intended for use as a com ponent of any article
	217	+	specified in this paragraph;
224	218
225		-	HB1005 HFLR Page 5
226		-	BOLD FACE denotes Committee Amendments. 1
	219	+	Req. No. 5070 Page 5 1
227	220		2
228	221		3
229	222		4
230	223		5
231	224		6
232	225		7
233	226		8
234	227		9
235	228		10
236	229		11
237	230		12
238	231		13
239	232		14
240	233		15
241	234		16
242	235		17
243	236		18
244	237		19
245	238		20
246	239		21
247	240		22
248	241		23
249	242		24
250	243
251		-	c. other than food, intended to affect the structure or
252		-	any function of the body of man or other animals, and
253		-	d. intended for use as a component of any article
254		-	specified in this paragraph;
255	244		provided, however, the term "drug" does not include devices or their
256	245		components, parts or accessories;
257	246		15. "Drug-dependent person" means a person who is using a
258	247		controlled dangerous substance and who is i n a state of psychic or
259	248		physical dependence, or both, arising from administration of that
260	249		controlled dangerous substance on a continuous basis. Drug
261	250		dependence is characterized by behavioral and other responses which
262	251		include a strong compulsion to take th e substance on a continuous
263	252		basis in order to experience its psychic effects, or to avoid the
264	253		discomfort of its absence;
265	254		16. "Harm-reduction services" means programs established to:
266	255		a. reduce the spread of infectious diseases related to
267	256		injection drug use,
268	257		b. reduce drug dependency, overdose deaths, and
269	258		associated complications, and
270	259		c. increase safe recovery and disposal of used syringes
271	260		and sharp waste;
272	261		17. "Home care agency" means any sole proprietorship,
273	262		partnership, association, corporation, or other organization which
274	263		administers, offers, or provides home care services, for a fee or
	264	+	pursuant to a contract for such services, to clients in their place
	265	+	of residence;
	266	+	17. 18. "Home care services" means skilled or personal care
	267	+	services provided to clients in their place of residence for a fee;
275	268
276		-	HB1005 HFLR Page 6
277		-	BOLD FACE denotes Committee Amendments. 1
	269	+	Req. No. 5070 Page 6 1
278	270		2
279	271		3
280	272		4
281	273		5
282	274		6
283	275		7
284	276		8
285	277		9
286	278		10
287	279		11
288	280		12
289	281		13
290	282		14
291	283		15
292	284		16
293	285		17
294	286		18
295	287		19
296	288		20
297	289		21
298	290		22
299	291		23
300	292		24
301	293
302		-	pursuant to a contract for such services, to clients in their place
303		-	of residence;
304		-	17. 18. "Home care services" means skilled or personal care
305		-	services provided to clients in their place of residence for a fee;
306	294		18. 19. "Hospice" means a centrally administered, nonprofit or
307	295		profit, medically directed, nurse -coordinated program which provides
308	296		a continuum of home and inpatient care for the terminally ill
309	297		patient and the patie nt's family. Such term shall also include a
310	298		centrally administered, nonprofit or profit, medically directed,
311	299		nurse-coordinated program if such program is licensed pursuant to
312	300		the provisions of the Uniform Controlled Dangerous Substances Act.
313	301		A hospice program offers palliative and supportive care to meet the
314	302		special needs arising out of the physical, emotional and spiritual
315	303		stresses which are experienced during the final stages of illness
316	304		and during dying and bereavement. This care is available twenty -
317	305		four (24) hours a day, seven (7) days a week, and is provided on the
318	306		basis of need, regardless of ability to pay. "Class A" Hospice
319	307		refers to Medicare certified hospices. "Class B" refers to all
320	308		other providers of hospice services;
321	309		19. 20. "Imitation controlled substance" means a substance that
322	310		is not a controlled dangerous substance, which by dosage unit
323	311		appearance, color, shape, size, markings or by representations made,
324	312		would lead a reasonable person to believe that the substance is a
325	313		controlled dangerous substance. In the event the appearance of the
	314	+	dosage unit is not reasonably sufficient to establish that the
	315	+	substance is an "imitation controlled substance ", the court or
	316	+	authority concerned should consider, in addition to all other
	317	+	factors, the following factors as related to "representations made "
326	318
327		-	HB1005 HFLR Page 7
328		-	BOLD FACE denotes Committee Amendments. 1
	319	+	Req. No. 5070 Page 7 1
329	320		2
330	321		3
331	322		4
332	323		5
333	324		6
334	325		7
335	326		8
336	327		9
337	328		10
338	329		11
339	330		12
340	331		13
341	332		14
342	333		15
343	334		16
344	335		17
345	336		18
346	337		19
347	338		20
348	339		21
349	340		22
350	341		23
351	342		24
352	343
353		-	dosage unit is not reasonably sufficient to establish that the
354		-	substance is an "imitation controlled subst ance", the court or
355		-	authority concerned should consider, in addition to all other
356		-	factors, the following factors as related to "representations made "
357	344		in determining whether the substance is an "imitation controlled
358	345		substance":
359	346		a. statements made by an owner or by any other person in
360	347		control of the substance concerning the nature of the
361	348		substance, or its use or effect,
362	349		b. statements made to the recipient that the substance
363	350		may be resold for inordinate profit,
364	351		c. whether the substance is packaged in a manner normally
365	352		used for illicit controlled substances,
366	353		d. evasive tactics or actions utilized by the owner or
367	354		person in control of the substance to avoid detection
368	355		by law enforcement authorities,
369	356		e. prior convictions, if any, of an owner, or any other
370	357		person in control of the object substance, under state
371	358		or federal law related to controlled substances or
372	359		fraud, and
373	360		f. the proximity of the substances to controlled
374	361		dangerous substances;
375	362		20. 21. "Immediate precursor" means a substance which the
376	363		Director has found to be and by regulation designates as being the
	364	+	principal compound commonly used or produced primari ly for use, and
	365	+	which is an immediate chemical intermediary used, or likely to be
	366	+	used, in the manufacture of a controlled dangerous substance, the
377	367
378		-	HB1005 HFLR Page 8
379		-	BOLD FACE denotes Committee Amendments. 1
	368	+	Req. No. 5070 Page 8 1
380	369		2
381	370		3
382	371		4
383	372		5
384	373		6
385	374		7
386	375		8
387	376		9
388	377		10
389	378		11
390	379		12
391	380		13
392	381		14
393	382		15
394	383		16
395	384		17
396	385		18
397	386		19
398	387		20
399	388		21
400	389		22
401	390		23
402	391		24
403	392
404		-	principal compound commonly used or produced primarily for use, and
405		-	which is an immediate chemical intermediary used, or likely to be
406		-	used, in the manufacture of a controlled dangerous substance, the
407	393		control of which is necessary to prevent, curtail or limit such
408	394		manufacture;
409	395		21. 22. "Laboratory" means a laboratory approved by the
410	396		Director as proper to be entrusted with the custody of controlled
411	397		dangerous substances and the use of controlled dangerous substances
412	398		for scientific and medical purposes and for purposes of instruction;
413	399		22. 23. "Manufacture" means the production, preparation,
414	400		propagation, compounding or processing of a controlled dangerous
415	401		substance, either directly or indirectly by extraction from
416	402		substances of natural or synthetic origin, or independently by means
417	403		of chemical synthesis or by a c ombination of extraction and chemical
418	404		synthesis. "Manufacturer" includes any person who packages,
419	405		repackages or labels any container of any controlled dangerous
420	406		substance, except practitioners who dispense or compound
421	407		prescription orders for delivery to t he ultimate consumer;
422	408		23. 24. "Marijuana" means all parts of the plant Cannabis
423	409		sativa L., whether growing or not; the seeds thereof; the resin
424	410		extracted from any part of such plant; and every compound,
425	411		manufacture, salt, derivative, mixture or preparatio n of such plant,
426	412		its seeds or resin, but shall not include:
	413	+	a. the mature stalks of such plant or fiber produced from
	414	+	such stalks,
427	415
428		-	HB1005 HFLR Page 9
429		-	BOLD FACE denotes Committee Amendments. 1
	416	+	Req. No. 5070 Page 9 1
430	417		2
431	418		3
432	419		4
433	420		5
434	421		6
435	422		7
436	423		8
437	424		9
438	425		10
439	426		11
440	427		12
441	428		13
442	429		14
443	430		15
444	431		16
445	432		17
446	433		18
447	434		19
448	435		20
449	436		21
450	437		22
451	438		23
452	439		24
453	440
454		-	a. the mature stalks of such plant or fiber produced from
455		-	such stalks,
456	441		b. oil or cake made from the seeds of such plant,
457	442		including cannabidiol derived from the seeds of the
458	443		marijuana plant,
459	444		c. any other compound, manufacture, salt, derivative,
460	445		mixture or preparation of such mature stalks (except
461	446		the resin extracted therefrom), including cannabidiol
462	447		derived from mature stalks, fiber, oil or cake,
463	448		d. the sterilized seed of such plant which is incapab le
464	449		of germination,
465	450		e. for any person participating in a clinical trial to
466	451		administer cannabidiol for the treatment of severe
467	452		forms of epilepsy pursuant to Section 2 -802 of this
468	453		title, a drug or substance approved by the federal
469	454		Food and Drug Administration for use by those
470	455		participants,
471	456		f. for any person or the parents, legal guardians or
472	457		caretakers of the person who have received a written
473	458		certification from a physician licensed in this state
474	459		that the person has been diagnosed by a physician as
475	460		having Lennox-Gastaut syndrome, Dravet syndrome, also
476	461		known as Severe Myoclonic Epilepsy of Infancy, or any
477	462		other severe form of epilepsy that is not adequately
	463	+	treated by traditional medical therapies, spasticity
	464	+	due to multiple sclerosis or due to paraplegia,
478	465
479		-	HB1005 HFLR Page 10
480		-	BOLD FACE denotes Committee Amendments. 1
	466	+	Req. No. 5070 Page 10 1
481	467		2
482	468		3
483	469		4
484	470		5
485	471		6
486	472		7
487	473		8
488	474		9
489	475		10
490	476		11
491	477		12
492	478		13
493	479		14
494	480		15
495	481		16
496	482		17
497	483		18
498	484		19
499	485		20
500	486		21
501	487		22
502	488		23
503	489		24
504	490
505		-	treated by traditional medical therapies, spasticity
506		-	due to multiple sclerosis or due to paraplegia,
507	491		intractable nausea and vomiting, appetite stimulation
508	492		with chronic wasting diseases, the substance
509	493		cannabidiol, a nonpsychoactive cannabinoid, found in
510	494		the plant Cannabis sativa L. or any other preparation
511	495		thereof, that has a tetrahydrocannabinol concentration
512	496		of not more than three -tenths of one percent (0.3%)
513	497		and that is delivered to the patient in the form of a
514	498		liquid,
515	499		g. any cannabidiol drug or substance approved by the
516	500		federal Food and Drug Administration-approved
517	501		cannabidiol drug or substance , or
518	502		h. industrial hemp, from the plant Cannabis sativa L. and
519	503		any part of such plant, whether growing or not, with a
520	504		delta-9 tetrahydrocannabinol concentration of not more
521	505		than three-tenths of one percent (0.3%) on a dry
522	506		weight basis which shall only be grown pursuant to the
523	507		Oklahoma Industrial Hemp Program and may be shipped
524	508		intrastate and interstate;
525	509		24. 25. "Medical purpose" means an intention to utilize a
526	510		controlled dangerous substance for physical or mental treatment, for
527	511		diagnosis, or for the prevention of a dise ase condition not in
	512	+	violation of any state or federal law and not for the purpose of
	513	+	satisfying physiological or psychological dependence or other abuse;
528	514
529		-	HB1005 HFLR Page 11
530		-	BOLD FACE denotes Committee Amendments. 1
	515	+	Req. No. 5070 Page 11 1
531	516		2
532	517		3
533	518		4
534	519		5
535	520		6
536	521		7
537	522		8
538	523		9
539	524		10
540	525		11
541	526		12
542	527		13
543	528		14
544	529		15
545	530		16
546	531		17
547	532		18
548	533		19
549	534		20
550	535		21
551	536		22
552	537		23
553	538		24
554	539
555		-	violation of any state or federal law and not for the purpose of
556		-	satisfying physiological or psychological dependence or other abuse;
557	540		25. 26. "Mid-level practitioner" means an Advanced Practice
558	541		Registered Nurse as defined and within p arameters specified in
559	542		Section 567.3a of Title 59 of the Oklahoma Statutes, or a certified
560	543		animal euthanasia technician as defined in Section 698.2 of Title 59
561	544		of the Oklahoma Statutes, or an animal control officer registered by
562	545		the Oklahoma State Bureau o f Narcotics and Dangerous Drugs Control
563	546		under subsection B of Section 2 -301 of this title within the
564	547		parameters of such officer 's duty under Sections 501 through 508 of
565	548		Title 4 of the Oklahoma Statutes;
566	549		26. 27. "Narcotic drug" means any of the following, whether
567	550		produced directly or indirectly by extraction from substances of
568	551		vegetable origin, or independently by means of chemical synthesis,
569	552		or by a combination of extraction and chemical synthesis:
570	553		a. opium, coca leaves and opiates,
571	554		b. a compound, manufact ure, salt, derivative or
572	555		preparation of opium, coca leaves or opiates,
573	556		c. cocaine, its salts, optical and geometric isomers, and
574	557		salts of isomers,
575	558		d. ecgonine, its derivatives, their salts, isomers and
576	559		salts of isomers, and
577	560		e. a substance, and any compound , manufacture, salt,
578	561		derivative or preparation thereof, which is chemically
	562	+	identical with any of the substances referred to in
	563	+	subparagraphs a through d of this paragraph, except
579	564
580		-	HB1005 HFLR Page 12
581		-	BOLD FACE denotes Committee Amendments. 1
	565	+	Req. No. 5070 Page 12 1
582	566		2
583	567		3
584	568		4
585	569		5
586	570		6
587	571		7
588	572		8
589	573		9
590	574		10
591	575		11
592	576		12
593	577		13
594	578		14
595	579		15
596	580		16
597	581		17
598	582		18
599	583		19
600	584		20
601	585		21
602	586		22
603	587		23
604	588		24
605	589
606		-	identical with any of the substances referred to in
607		-	subparagraphs a through d of this paragraph, except
608	590		that the words "narcotic drug" as used in Section 2 -
609	591		101 et seq. of this titl e shall not include
610	592		decocainized coca leaves or extracts of coca leaves,
611	593		which extracts do not contain cocaine or ecgonine;
612	594		27. 28. "Opiate" or "opioid" means any Schedule II, III, IV or
613	595		V substance having an addiction -forming or addiction -sustaining
614	596		liability similar to morphine or being capable of conversion into a
615	597		drug having such addiction -forming or addiction -sustaining
616	598		liability. The terms do not include, unless specifically designated
617	599		as controlled under the Uniform Controlled Dangerous Substances Act,
618	600		the dextrorotatory isomer of 3 -methoxy-n-methyl-morphinan and its
619	601		salts (dextromethorphan). The terms do include the racemic and
620	602		levorotatory forms;
621	603		28. 29. "Opium poppy" means the plant of the species Papaver
622	604		somniferum L., except the seeds thereof ;
623	605		29. 30. "Peace officer" means a police officer, sheriff, deputy
624	606		sheriff, district attorney 's investigator, investigator from the
625	607		Office of the Attorney General, or any other person elected or
626	608		appointed by law to enforce any of the criminal laws of this state
627	609		or of the United States;
	610	+	30. 31. "Person" means an individual, corporation, government
	611	+	or governmental subdivision or agency, business trust, estate,
	612	+	trust, partnership or association, or any other legal entity;
628	613
629		-	HB1005 HFLR Page 13
630		-	BOLD FACE denotes Committee Amendments. 1
	614	+	Req. No. 5070 Page 13 1
631	615		2
632	616		3
633	617		4
634	618		5
635	619		6
636	620		7
637	621		8
638	622		9
639	623		10
640	624		11
641	625		12
642	626		13
643	627		14
644	628		15
645	629		16
646	630		17
647	631		18
648	632		19
649	633		20
650	634		21
651	635		22
652	636		23
653	637		24
654	638
655		-	30. 31. "Person" means an individual, corporation, government
656		-	or governmental subdivision or agency, business trust, estate,
657		-	trust, partnership or association, or any other legal entity;
658	639		31. 32. "Poppy straw" means all parts, except the seeds, of the
659	640		opium poppy, after mowing;
660	641		32. 33. "Practitioner" means:
661	642		a. (1) a medical doctor or osteopathic physician,
662	643		(2) a dentist,
663	644		(3) a podiatrist,
664	645		(4) an optometrist,
665	646		(5) a veterinarian,
666	647		(6) a physician assistant or Advanced Practice
667	648		Registered Nurse under the supervision of a
668	649		licensed medical doctor or osteopathic physician,
669	650		(7) a scientific investigator, or
670	651		(8) any other person,
671	652		licensed, registered or otherwise permitted to
672	653		prescribe, distribute, dispense, conduct research with
673	654		respect to, use for scientific purposes or administer
674	655		a controlled dangerous substance in the course of
675	656		professional practice or research in this state, or
676	657		b. a pharmacy, hospital, laboratory or other institution
677	658		licensed, registered or otherwise permitted to
678	659		distribute, dispense, conduct research with respect
	660	+	to, use for scientific purposes or administer a
	661	+	controlled dangerous substance in the course of
	662	+	professional practice or research in this state;
679	663
680		-	HB1005 HFLR Page 14
681		-	BOLD FACE denotes Committee Amendments. 1
	664	+	Req. No. 5070 Page 14 1
682	665		2
683	666		3
684	667		4
685	668		5
686	669		6
687	670		7
688	671		8
689	672		9
690	673		10
691	674		11
692	675		12
693	676		13
694	677		14
695	678		15
696	679		16
697	680		17
698	681		18
699	682		19
700	683		20
701	684		21
702	685		22
703	686		23
704	687		24
705	688
706		-	to, use for scientific purposes or administer a
707		-	controlled dangerous substance in the course of
708		-	professional practice or research in this state;
709	689		33. 34. "Production" includes the manufacture, planting,
710	690		cultivation, growing or harvesting of a controlled dangerous
711	691		substance;
712	692		34. 35. "State" means the State of Oklahoma or any other state
713	693		of the United States;
714	694		35. 36. "Ultimate user" means a person who lawfully possesses a
715	695		controlled dangerous substance for the person's own use or for the
716	696		use of a member of the person 's household or for administration to
717	697		an animal owned by the person or by a member of the person 's
718	698		household;
719	699		36. 37. "Drug paraphernalia" means all equipment, products and
720	700		materials of any kin d which are used, intended for use, or fashioned
721	701		specifically for use in planting, propagating, cultivating, growing,
722	702		harvesting, manufacturing, compounding, converting, producing,
723	703		processing, preparing, testing, analyzing, packaging, repackaging,
724	704		storing, containing, concealing, injecting, ingesting, inhaling or
725	705		otherwise introducing into the human body, a controlled dangerous
726	706		substance in violation of the Uniform Controlled Dangerous
727	707		Substances Act including, but not limited to:
728	708		a. kits used, intended for use, or fashioned specifically
729	709		for use in planting, propagating, cultivating, growing
	710	+	or harvesting of any species of plant which is a
	711	+	controlled dangerous substance or from which a
	712	+	controlled dangerous substance can be derived,
730	713
731		-	HB1005 HFLR Page 15
732		-	BOLD FACE denotes Committee Amendments. 1
	714	+	Req. No. 5070 Page 15 1
733	715		2
734	716		3
735	717		4
736	718		5
737	719		6
738	720		7
739	721		8
740	722		9
741	723		10
742	724		11
743	725		12
744	726		13
745	727		14
746	728		15
747	729		16
748	730		17
749	731		18
750	732		19
751	733		20
752	734		21
753	735		22
754	736		23
755	737		24
756	738
757		-	or harvesting of any species of plant which is a
758		-	controlled dangerous substance or from which a
759		-	controlled dangerous substance can be derived,
760	739		b. kits used, intended for use, or fashioned specifically
761	740		for use in manufacturing, compounding, converting,
762	741		producing, processing or preparing controlled
763	742		dangerous substances,
764	743		c. isomerization devices used, intended for use, or
765	744		fashioned specifically for use in increasing the
766	745		potency of any species of plant which is a controlled
767	746		dangerous substance,
768	747		d. testing equipment used, intended for use, or fashioned
769	748		specifically for use in identifying, or in analyzing
770	749		the strength, effectiveness or purity of controlled
771	750		dangerous substances,
772	751		e. scales and balances used, intended for use, or
773	752		fashioned specifically for use in weighing or
774	753		measuring controlled dangerous substances,
775	754		f. diluents and adulterants, such as quinine
776	755		hydrochloride, mannitol, mannite, dextrose and
777	756		lactose, used, intended f or use, or fashioned
778	757		specifically for use in cutting controlled dangerous
779	758		substances,
	759	+	g. separation gins and sifters used, intended for use, or
	760	+	fashioned specifically for use in removing twigs and
	761	+	seeds from, or in otherwise cleaning or refining,
	762	+	marijuana,
780	763
781		-	HB1005 HFLR Page 16
782		-	BOLD FACE denotes Committee Amendments. 1
	764	+	Req. No. 5070 Page 16 1
783	765		2
784	766		3
785	767		4
786	768		5
787	769		6
788	770		7
789	771		8
790	772		9
791	773		10
792	774		11
793	775		12
794	776		13
795	777		14
796	778		15
797	779		16
798	780		17
799	781		18
800	782		19
801	783		20
802	784		21
803	785		22
804	786		23
805	787		24
806	788
807		-	g. separation gins and sifters used, intended for use, or
808		-	fashioned specifically for use in removing twigs and
809		-	seeds from, or in otherwise cleaning or refining,
810		-	marijuana,
811	789		h. blenders, bowls, containers, spoons and mixing devices
812	790		used, intended for use, or fashioned specifically for
813	791		use in compounding controlled dangerous substances,
814	792		i. capsules, balloons, envelopes and other containers
815	793		used, intended for use, or fashioned specifically for
816	794		use in packaging small quantities of controlled
817	795		dangerous substances,
818	796		j. containers and other objects used, intended for use,
819	797		or fashioned specifically for use in parenterally
820	798		injecting controlled dangerous substances into the
821	799		human body,
822	800		k. hypodermic syringes, needles and other objects used,
823	801		intended for use, or fashioned specifically for use in
824	802		parenterally injecting controlled dangerous substances
825	803		into the human body except as authorized by Section 3
826	804		of this act,
827	805		l. objects used, intended for use, or fashioned
828	806		specifically for use in ingesting, inhaling or
829	807		otherwise introducing marijuana, cocaine, hashish or
830	808		hashish oil into the human body, such as:
	809	+	(1) metal, wooden, acrylic, glass, stone, plastic or
	810	+	ceramic pipes with or without scree ns, permanent
	811	+	screens, hashish heads or punctured metal bowls,
	812	+	(2) water pipes,
831	813
832		-	HB1005 HFLR Page 17
833		-	BOLD FACE denotes Committee Amendments. 1
	814	+	Req. No. 5070 Page 17 1
834	815		2
835	816		3
836	817		4
837	818		5
838	819		6
839	820		7
840	821		8
841	822		9
842	823		10
843	824		11
844	825		12
845	826		13
846	827		14
847	828		15
848	829		16
849	830		17
850	831		18
851	832		19
852	833		20
853	834		21
854	835		22
855	836		23
856	837		24
857	838
858		-	(1) metal, wooden, acrylic, glass, stone, plastic or
859		-	ceramic pipes with or without screens, permanent
860		-	screens, hashish heads or punctured metal bowls,
861		-	(2) water pipes,
862	839		(3) carburetion tubes and devices,
863	840		(4) smoking and carburetion masks,
864	841		(5) roach clips, meaning objects used to hold burning
865	842		material, such as a marijuana cigarette, that has
866	843		become too small or too short to be held in the
867	844		hand,
868	845		(6) miniature cocaine spoons and cocaine vials,
869	846		(7) chamber pipes,
870	847		(8) carburetor pipes,
871	848		(9) electric pipes,
872	849		(10) air-driven pipes,
873	850		(11) chillums,
874	851		(12) bongs, or
875	852		(13) ice pipes or chillers,
876	853		m. all hidden or novelty pipes, and
877	854		n. any pipe that has a tobacco bowl or chamber of less
878	855		than one-half (1/2) inch in diameter in which there is
879	856		any detectable residue of any controlled dangerous
880	857		substance as defined in this section or any other
881	858		substances not legal fo r possession or use;
	859	+	provided, however, the term "drug paraphernalia" shall not include
	860	+	separation gins intended for use in preparing tea or spice, clamps
	861	+	used for constructing electrical equipment, water pipes designed for
	862	+	ornamentation in which no detect able amount of an illegal substance
882	863
883		-	HB1005 HFLR Page 18
884		-	BOLD FACE denotes Committee Amendments. 1
	864	+	Req. No. 5070 Page 18 1
885	865		2
886	866		3
887	867		4
888	868		5
889	869		6
890	870		7
891	871		8
892	872		9
893	873		10
894	874		11
895	875		12
896	876		13
897	877		14
898	878		15
899	879		16
900	880		17
901	881		18
902	882		19
903	883		20
904	884		21
905	885		22
906	886		23
907	887		24
908	888
909		-	provided, however, the term "drug paraphernalia" shall not include
910		-	separation gins intended for use in preparing tea or spice, clamps
911		-	used for constructing electrical equipment, water pipes designed for
912		-	ornamentation in which no detectable amount of an illegal substance
913	889		is found or pipes designed and used solely for smoking tobacco,
914	890		traditional pipes of an American Indian tribal religious ceremony,
915	891		or antique pipes that are thirty (30) years of age or older;
916	892		37.
917	893		38. a. "Synthetic controlled substance" means a substance:
918	894		(1) the chemical structure of which is substantially
919	895		similar to the chemical structure of a controlled
920	896		dangerous substance in Schedule I or II,
921	897		(2) which has a stimulant, depressant, or
922	898		hallucinogenic effect on the centra l nervous
923	899		system that is substantially similar to or
924	900		greater than the stimulant, depressant or
925	901		hallucinogenic effect on the central nervous
926	902		system of a controlled dangerous substance in
927	903		Schedule I or II, or
928	904		(3) with respect to a particular person, which su ch
929	905		person represents or intends to have a stimulant,
930	906		depressant, or hallucinogenic effect on the
931	907		central nervous system that is substantially
932	908		similar to or greater than the stimulant,
	909	+	depressant, or hallucinogenic effect on the
	910	+	central nervous system of a controlled dangerous
	911	+	substance in Schedule I or II.
933	912
934		-	HB1005 HFLR Page 19
935		-	BOLD FACE denotes Committee Amendments. 1
	913	+	Req. No. 5070 Page 19 1
936	914		2
937	915		3
938	916		4
939	917		5
940	918		6
941	919		7
942	920		8
943	921		9
944	922		10
945	923		11
946	924		12
947	925		13
948	926		14
949	927		15
950	928		16
951	929		17
952	930		18
953	931		19
954	932		20
955	933		21
956	934		22
957	935		23
958	936		24
959	937
960		-	depressant, or hallucinogenic effect on the
961		-	central nervous system of a controlled dangerous
962		-	substance in Schedule I or II.
963	938		b. The designation of gamma butyrolactone or any other
964	939		chemical as a precursor, pursuant to Section 2 -322 of
965	940		this title, does not preclude a finding pursuant to
966	941		subparagraph a of this paragraph that the c hemical is
967	942		a synthetic controlled substance.
968	943		c. "Synthetic controlled substance " does not include:
969	944		(1) a controlled dangerous substance,
970	945		(2) any substance for which there is an approved new
971	946		drug application,
972	947		(3) with respect to a particular person any
973	948		substance, if an exemption is in effect for
974	949		investigational use, for that person under the
975	950		provisions of Section 505 of the Federal Food,
976	951		Drug and Cosmetic Act, Title 21 of the United
977	952		States Code, Section 355, to the extent conduct
978	953		with respect to such substan ce is pursuant to
979	954		such exemption, or
980	955		(4) any substance to the extent not intended for
981	956		human consumption before such an exemption takes
982	957		effect with respect to that substance.
	958	+	d. Prima facie evidence that a substance containing
	959	+	salvia divinorum has been enha nced, concentrated or
	960	+	chemically or physically altered shall give rise to a
983	961
984		-	HB1005 HFLR Page 20
985		-	BOLD FACE denotes Committee Amendments. 1
	962	+	Req. No. 5070 Page 20 1
986	963		2
987	964		3
988	965		4
989	966		5
990	967		6
991	968		7
992	969		8
993	970		9
994	971		10
995	972		11
996	973		12
997	974		13
998	975		14
999	976		15
1000	977		16
1001	978		17
1002	979		18
1003	980		19
1004	981		20
1005	982		21
1006	983		22
1007	984		23
1008	985		24
1009	986
1010		-	d. Prima facie evidence that a substance containing
1011		-	salvia divinorum has been enhanced, concentrated or
1012		-	chemically or physically altered shall give rise to a
1013	987		rebuttable presumption that the substance is a
1014	988		synthetic controlled substance;
1015	989		38. 39. "Tetrahydrocannabinols " means all substances that have
1016	990		been chemically synthesized to emulat e the tetrahydrocannabinols of
1017	991		marijuana;
1018	992		39. 40. "Isomer" means the optical isomer, except as used in
1019	993		subsections C and F of Section 2 -204 of this title and paragraph 4
1020	994		of subsection A of Section 2 -206 of this title. As used in
1021	995		subsections C and F of Se ction 2-204 of this title, "isomer" means
1022	996		the optical, positional or geometric isomer. As used in paragraph 4
1023	997		of subsection A of Section 2 -206 of this title, the term "isomer"
1024	998		means the optical or geometric isomer;
1025	999		40. 41. "Hazardous materials" means materials, whether solid,
1026	1000		liquid or gas, which are toxic to human, animal, aquatic or plant
1027	1001		life, and the disposal of which materials is controlled by state or
1028	1002		federal guidelines;
1029	1003		41. 42. "Anhydrous ammonia" means any substance that exhibits
1030	1004		cryogenic evaporative behavior and tests positive for ammonia;
1031	1005		42. 43. "Acute pain" means pain, whether resulting from
1032	1006		disease, accidental or intentional trauma or other cause, that the
1033	1007		practitioner reasonably expects to last only a short period of time.
	1008	+	"Acute pain" does not include chronic pain, pain being treated as
	1009	+	part of cancer care, hospice or other end -of-life care, or pain
	1010	+	being treated as part of palliative care;
1034	1011
1035		-	HB1005 HFLR Page 21
1036		-	BOLD FACE denotes Committee Amendments. 1
	1012	+	Req. No. 5070 Page 21 1
1037	1013		2
1038	1014		3
1039	1015		4
1040	1016		5
1041	1017		6
1042	1018		7
1043	1019		8
1044	1020		9
1045	1021		10
1046	1022		11
1047	1023		12
1048	1024		13
1049	1025		14
1050	1026		15
1051	1027		16
1052	1028		17
1053	1029		18
1054	1030		19
1055	1031		20
1056	1032		21
1057	1033		22
1058	1034		23
1059	1035		24
1060	1036
1061		-	"Acute pain" does not include chronic pain, pain being treated as
1062		-	part of cancer care, hospice or other end -of-life care, or pain
1063		-	being treated as part of palliative care;
1064	1037		43. 44. "Chronic pain" means pain that persists beyond the
1065	1038		usual course of an acute disease or hea ling of an injury. "Chronic
1066	1039		pain" may or may not be associated with an acute or chronic
1067	1040		pathologic process that causes continuous or intermittent pain over
1068	1041		months or years;
1069	1042		44. 45. "Initial prescription " means a prescription issued to a
1070	1043		patient who:
1071	1044		a. has never not previously been issued a prescription
1072	1045		for the drug or its pharmaceutical equivalent in the
1073	1046		past year, or
1074	1047		b. requires a prescription for the drug or its
1075	1048		pharmaceutical equivalent due to a surgical procedure
1076	1049		or new acute event and has previously had a
1077	1050		prescription for the drug or its pharmaceutical
1078	1051		equivalent within the past year.
1079	1052		When determining whether a patient was previously issued a
1080	1053		prescription for a drug or its pharmaceutical equivalent, the
1081	1054		practitioner shall consult with the patient and review the medical
1082	1055		record and prescription monitoring information of the patient;
1083	1056		45. 46. "Patient-provider agreement" means a written contract
1084	1057		or agreement that is executed between a practitioner and a patient,
	1058	+	prior to the commencement of treatment for chronic pain using an
	1059	+	opioid drug as a means to:
1085	1060
1086		-	HB1005 HFLR Page 22
1087		-	BOLD FACE denotes Committee Amendments. 1
	1061	+	Req. No. 5070 Page 22 1
1088	1062		2
1089	1063		3
1090	1064		4
1091	1065		5
1092	1066		6
1093	1067		7
1094	1068		8
1095	1069		9
1096	1070		10
1097	1071		11
1098	1072		12
1099	1073		13
1100	1074		14
1101	1075		15
1102	1076		16
1103	1077		17
1104	1078		18
1105	1079		19
1106	1080		20
1107	1081		21
1108	1082		22
1109	1083		23
1110	1084		24
1111	1085
1112		-	prior to the commencement of treatment for chronic pain using an
1113		-	opioid drug as a means to:
1114	1086		a. explain the possible risk of development of physical
1115	1087		or psychological dependence in the patient and prevent
1116	1088		the possible development of addiction,
1117	1089		b. document the understanding of both the practitioner
1118	1090		and the patient regarding the patient -provider
1119	1091		agreement of the patient,
1120	1092		c. establish the rights of the patient in association
1121	1093		with treatment and the obligations of the patient in
1122	1094		relation to the responsible use, discontinuation of
1123	1095		use, and storage of opioi d drugs, including any
1124	1096		restrictions on the refill of prescriptions or the
1125	1097		acceptance of opioid prescriptions from practitioners,
1126	1098		d. identify the specific medications and other modes of
1127	1099		treatment, including physical therapy or exercise,
1128	1100		relaxation or psycho logical counseling, that are
1129	1101		included as a part of the patient -provider agreement,
1130	1102		e. specify the measures the practitioner may employ to
1131	1103		monitor the compliance of the patient including, but
1132	1104		not limited to, random specimen screens and pill
1133	1105		counts, and
1134	1106		f. delineate the process for terminating the agreement,
1135	1107		including the consequences if the practitioner has
	1108	+	reason to believe that the patient is not complying
	1109	+	with the terms of the agreement. Compliance with the
1136	1110
1137		-	HB1005 HFLR Page 23
1138		-	BOLD FACE denotes Committee Amendments. 1
	1111	+	Req. No. 5070 Page 23 1
1139	1112		2
1140	1113		3
1141	1114		4
1142	1115		5
1143	1116		6
1144	1117		7
1145	1118		8
1146	1119		9
1147	1120		10
1148	1121		11
1149	1122		12
1150	1123		13
1151	1124		14
1152	1125		15
1153	1126		16
1154	1127		17
1155	1128		18
1156	1129		19
1157	1130		20
1158	1131		21
1159	1132		22
1160	1133		23
1161	1134		24
1162	1135
1163		-	reason to believe that the patient is not complying
1164		-	with the terms of the agreement. Compliance with the
1165	1136		"consent items" shall constitute a valid, infor med
1166	1137		consent for opioid therapy. The practitioner shall be
1167	1138		held harmless from civil litigation for failure to
1168	1139		treat pain if the event occurs because of nonadherence
1169	1140		by the patient with any of the provisions of the
1170	1141		patient-provider agreement;
1171	1142		46. 47. "Serious illness" means a medical illness or physical
1172	1143		injury or condition that substantially affects quality of life for
1173	1144		more than a short period of time. "Serious illness" includes, but
1174	1145		is not limited to, Alzheimer 's disease or related dementias, lung
1175	1146		disease, cancer, heart failure, renal failure, liver failure or
1176	1147		chronic, unremitting or intractable pain such as neuropathic pain;
1177	1148		and
1178	1149		47. 48. "Surgical procedure" means a procedure that is
1179	1150		performed for the purpose of structurally altering the human body by
1180	1151		incision or destruction of tissues as part of the practice of
1181	1152		medicine. This term includes the diagnostic or therapeutic
1182	1153		treatment of conditions or disease processes by use of instruments
1183	1154		such as lasers, ultrasound, ionizing, radiation, scalpels, probes or
1184	1155		needles that cause localized alteration or transportation of live
1185	1156		human tissue by cutting, burning, vaporizing, freezing, suturing,
1186	1157		probing or manipulating by closed reduction for major dislocations
	1158	+	or fractures, or otherwise altering by any mechanical, the rmal,
	1159	+	light-based, electromagnetic or chemical means.
1187	1160
1188		-	HB1005 HFLR Page 24
1189		-	BOLD FACE denotes Committee Amendments. 1
	1161	+	Req. No. 5070 Page 24 1
1190	1162		2
1191	1163		3
1192	1164		4
1193	1165		5
1194	1166		6
1195	1167		7
1196	1168		8
1197	1169		9
1198	1170		10
1199	1171		11
1200	1172		12
1201	1173		13
1202	1174		14
1203	1175		15
1204	1176		16
1205	1177		17
1206	1178		18
1207	1179		19
1208	1180		20
1209	1181		21
1210	1182		22
1211	1183		23
1212	1184		24
1213	1185
1214		-	or fractures, or otherwise altering by any mechanical, thermal,
1215		-	light-based, electromagnetic or chemical means.
1216	1186		SECTION 2. AMENDATORY 63 O.S. 2011, Section 2 -101.1, is
1217	1187		amended to read as follows:
1218	1188		Section 2-101.1 In determining whether an object is "drug
1219	1189		paraphernalia", a court or jury shall consider, in addition to all
1220	1190		other logically relevant factors, the following:
1221	1191		1. Statements by an owner or by anyone in control of the object
1222	1192		concerning its use;
1223	1193		2. The proximity of the object, in time and space, to a direct
1224	1194		violation of the Uniform Controlled Dangerous Substances Act;
1225	1195		3. The proximity of the object to controlled dangerous
1226	1196		substances;
1227	1197		4. The existence of any residue of controlled dangerous
1228	1198		substances on the object;
1229	1199		5. Direct or circumstantial evidence of the intent of an owner,
1230	1200		or of anyone in control of the object, to deliver it to any person
1231	1201		who intends to use the object to facilitate a violation of the
1232	1202		Uniform Controlled Dangerous Substances Act. The innocence of an
1233	1203		owner, or of anyone in control of the object, as to a direct
1234	1204		violation of this act shall not prevent a finding that the object is
1235	1205		intended for use, or fashioned specifically for use, as drug
1236	1206		paraphernalia;
	1207	+	6. Instructions, oral or written, provided with the object
	1208	+	which either state directly or imply that the object is to be used
	1209	+	for the consumption of controlled dangerous substances;
1237	1210
1238		-	HB1005 HFLR Page 25
1239		-	BOLD FACE denotes Committee Amendments. 1
	1211	+	Req. No. 5070 Page 25 1
1240	1212		2
1241	1213		3
1242	1214		4
1243	1215		5
1244	1216		6
1245	1217		7
1246	1218		8
1247	1219		9
1248	1220		10
1249	1221		11
1250	1222		12
1251	1223		13
1252	1224		14
1253	1225		15
1254	1226		16
1255	1227		17
1256	1228		18
1257	1229		19
1258	1230		20
1259	1231		21
1260	1232		22
1261	1233		23
1262	1234		24
1263	1235
1264		-	6. Instructions, oral or written, provided with the object
1265		-	which either state directly or imply that the object is to be used
1266		-	for the consumption of controlled dangerous substances;
1267	1236		7. Descriptive materials accompanying the object which explain
1268	1237		or depict its use as an object for the consumption of controlled
1269	1238		dangerous substances;
1270	1239		8. The manner in which the object is displayed for sale;
1271	1240		9. Whether the owner, or anyone in control of the object, is a
1272	1241		legitimate supplier of like or related items to the community, such
1273	1242		as a licensed distributor or dealer of tobacco products;
1274	1243		10. Direct or circumstantial evidence of t he ratio of sales of
1275	1244		the object or objects to the total sales of the business enterprise;
1276	1245		11. The existence and scope of legitimate uses for the object
1277	1246		in the community; and
1278	1247		12. Expert testimony concerning its use.
1279	1248		Provided, nothing in this section shall apply to objects in the
1280	1249		possession of harm-reduction services providers as authorized by
1281	1250		Section 3 of this act.
1282	1251		SECTION 3. NEW LAW A new section of law to be codified
1283	1252		in the Oklahoma Statutes as Section 2-1101 of Title 63, unless there
1284	1253		is created a duplication in numbering, reads as follows:
1285	1254		A. Until July 1, 2026, the following are hereby authorized to
1286	1255		engage in harm-reduction services:
	1256	+	1. Government entities including, but not limited to, the State
	1257	+	Department of Health and the Ok lahoma Department of Mental Health
	1258	+	and Substance Abuse Services; provided, no state dollars shall be
	1259	+	used to purchase hypodermic needles;
1287	1260
1288		-	HB1005 HFLR Page 26
1289		-	BOLD FACE denotes Committee Amendments. 1
	1261	+	Req. No. 5070 Page 26 1
1290	1262		2
1291	1263		3
1292	1264		4
1293	1265		5
1294	1266		6
1295	1267		7
1296	1268		8
1297	1269		9
1298	1270		10
1299	1271		11
1300	1272		12
1301	1273		13
1302	1274		14
1303	1275		15
1304	1276		16
1305	1277		17
1306	1278		18
1307	1279		19
1308	1280		20
1309	1281		21
1310	1282		22
1311	1283		23
1312	1284		24
1313	1285
1314		-	1. Government entities including, but not limited to, the State
1315		-	Department of Health and the Oklahoma Department of Mental Health
1316		-	and Substance Abuse Services; provided, no state dollars shall be
1317		-	used to purchase hypodermic needles;
1318	1286		2. Religious institutions or churches;
1319	1287		3. Nonprofit organizations;
1320	1288		4. For-profit companies;
1321	1289		5. Nongovernment entities partnering with a government agency;
1322	1290		and
1323	1291		6. Tribal governments.
1324	1292		B. Those offering harm-reduction services shall register with
1325	1293		the State Department of Health and may engage in the following
1326	1294		activities in order to reduce the use of drugs, prevent outbr eaks of
1327	1295		infectious diseases, and reduce morbidity among people who use
1328	1296		injection drugs:
1329	1297		1. Offer referrals and resources to treat substance use
1330	1298		disorders;
1331	1299		2. Provide education on the risk of transmission of infectious
1332	1300		diseases, including human immunodefi ciency virus (HIV) and viral
1333	1301		hepatitis;
1334	1302		3. Rapid testing for HIV, hepatitis C, and sexually transmitted
1335	1303		infections (STIs);
1336	1304		4. Referrals for medical and mental health services;
1337	1305		5. Collect used hypodermic needles for safe disposal ;
	1306	+	6. Possess and distribute hypodermic needles, cleaning kits,
	1307	+	test kits, and opioid antagonists; and
1338	1308
1339		-	HB1005 HFLR Page 27
1340		-	BOLD FACE denotes Committee Amendments. 1
	1309	+	Req. No. 5070 Page 27 1
1341	1310		2
1342	1311		3
1343	1312		4
1344	1313		5
1345	1314		6
1346	1315		7
1347	1316		8
1348	1317		9
1349	1318		10
1350	1319		11
1351	1320		12
1352	1321		13
1353	1322		14
1354	1323		15
1355	1324		16
1356	1325		17
1357	1326		18
1358	1327		19
1359	1328		20
1360	1329		21
1361	1330		22
1362	1331		23
1363	1332		24
1364	1333
1365		-	6. Possess and distribute hypodermic needles, cleaning kits,
1366		-	test kits, and opioid antagonists; and
1367	1334		7. Rapid substance-testing products used, intended for use, or
1368	1335		fashioned specifically for use in identi fying or analyzing the
1369	1336		potency or toxicity of unknown substances.
1370	1337		C. Registered providers of harm -reduction services shall report
1371	1338		at least quarterly to the State Department of Health:
1372	1339		1. The number of clients served, including basic demographic
1373	1340		information;
1374	1341		2. Number and type of referrals provided;
1375	1342		3. Number of syringes, tes t kits, and antagonists distributed;
1376	1343		4. Number of used syringes collected; and
1377	1344		5. Number of rapid HIV and viral hepatitis tests performed,
1378	1345		including the number of reactive test results.
1379	1346		D. The State Department of Health shall promulgate rules for
1380	1347		the implementation of this section.
1381	1348		SECTION 4. It being immediately necessary for the preservation
1382	1349		of the public peace, health or safety, an emergency is hereby
1383	1350		declared to exist, by reason whereof this act shall take effect and
1384	1351		be in full force from and after its passage and approval.
1385	1352
1386		-	COMMITTEE REPORT BY: COMMITTEE ON PUBLIC SAFETY, dated 02/09/2021 -
1387		-	DO PASS, As Coauthored.
	1353	+	58-1-5070 AB 10/12/20